The use of budesonide in the treatment of autoimmune hepatitis in Canada

Canadian Journal of Gastroenterology

Volumn 22, Issue 4, 2008, Pages 388-392

  Zandieh, Iman ^a   Krygier, Darin ^a   Wong, Victor ^b   Howard, John ^b   Worobetz, Lawrence ^c   Minuk, Gerald ^d   Witt Sullivan, Helga ^e   Yoshida, Eric M ^a,f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Autoimmune; Budesonide; Hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; PREDNISONE; SMOOTH MUSCLE ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHINGOID SYNDROME; DRUG INDICATION; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; GUILLAIN BARRE SYNDROME; HEALTH CARE ORGANIZATION; HUMAN; INFORMATION PROCESSING; LEUKOPENIA; MANIA; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHOOL CHILD; STEVENS JOHNSON SYNDROME; TEACHING HOSPITAL; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 44649191187     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/509459     Document Type: Article

References (47)

1. Czaja AJ, Freese DK, for the American Association for the Study Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-97.
2. Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002;22:339-52.
3. Boberg KM. Prevalence and epidemiology of autoimmune hepatitis Clin Liver Dis 2002;6:635-47.
4. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103.
5. Johnson PJ, McFarlane IG, Alvarez F, et al. Meeting report: International autoimmune hepatitis group. Hepatology 1993;18:998-1005.
6. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
7. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis Gastroenterology 1972;63:820-33.
8. Mistilis SP, Skyring AP, Blackburn CR. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Australas Ann Med 1968;17:214-23.
9. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome. Hepatology 1998;28:638-45.
10. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999;68:253-6.
11. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40:159-85.
12. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1:735-7.
13. Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001;32:428-30.
14. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984;4:622-7.
15. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission:. Uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981;304:5-9.
16. Schalm SW, Ammon HV, Summerskill WH. Failure of customary treatment in chronic active liver disease: Causes management. Ann Clin Res 1976;8:221-7.
17. Stellon AJ, Hegarty JE, Portmann B, Williams R. Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1985;1:668-70.
18. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988;8:781-4.
19. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-63.
20. Kanzler S, Gerken G, Lohr H, Galle PR, Meyer zurn Buschenfelde KH, Lohse AW. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001;34:354-5.
21. Jackson LD, Song E. Cyclosporin the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995;36:459-61.
22. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J Hepatol 1994;21:1040-7.
23. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999;94:241-8.
24. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001;46:1321-7.
25. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosprorine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7.
26. Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006;43:635-9.
27. Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998;13:490-5.
28. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial. Hepatology 1999;30:1381-6.
29. Schuppan D, Herold C, Strobel D, Schneider HT, Hahn ET. Successful treatment of therapy-refractory autoimmune hepatitis with mycophenolate mofetil. Hepatology 1998;28:A1960. (Abst)
30. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5.
31. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18:321-6.
32. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: The Canadian Association for the Study of Liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005;25:723-7.
33. Venkataramani A, Jones MB, Sorrell MF. Methotrexate therapy for refractory chronic active autoimmune hepatitis. Am J Gastroenterol 2001;96:3432-4.
34. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29:990-3.
35. Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z Gastroenterol 1997;35:571-8.
36. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoinimune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996;110:271-4.
37. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995;90:771-6.
38. McClements BM, Callender ME. D-penicillamine therapy in patients with HBsAg-negative chronic active hepatitis and major prednisilone-induced adverse effects. J Hepatol 1990;11:322-5.
39. Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005;25:927-34.
40. Csepregi A, Rocken C, Treiber G, Malfertheiner, P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006;12:1362-6.
41. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8:585-90.
42. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119:1312-6.
43. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmume hepatitis. Hepatology 2002;35:7-13.
44. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836-41.
45. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.
46. Keller R, Stoll R, Foerster EC, Gutsche N, Domschke W. Oral budesonide therapy for steroid-dependent ulcerative colitis: A pilot trial. Aliment Pharmacol Ther 1997;11:1047-52.
47. Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: A randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2002;123:978-84.